Optalgin Neo (Metamizole Sodium Monohydrate)

Metamizole sodium, the active ingredient in Optalgin Neo, is a pyrazolone analgesic presented as an oral formulation for oral use. It is indicated for mild to moderate pain, fever, postoperative pain and colic or visceral pain in adult patients. GNH USA supplies Optalgin Neo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Optalgin Neo, a pyrazolone analgesic, is used to manage several pain‑related conditions and fever. - Pain: provides relief of mild to moderate nociceptive pain. - Fever: reduces elevated body temperature. - Post‑operative pain: offers analgesia after surgical procedures. - Colic and visceral pain: alleviates abdominal cramping and visceral discomfort.

Adverse reactions may occur with Metamizole sodium use.

Common Side Effects: - Nausea: occasional upset stomach and vomiting. - Dizziness: transient light‑headedness or vertigo. - Rash: mild skin irritation or erythema. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening. - Anaphylaxis: acute allergic reaction with respiratory distress. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic or renal impairment: abnormal liver enzymes or reduced kidney function.

Metamizole sodium should be used with caution and under medical supervision. - Medical supervision: ensure prescription and monitoring by a healthcare professional. - Blood count monitoring: regular hematologic tests to detect agranulocytosis. - Hypersensitivity: avoid in patients with known allergy to pyrazolones. - Renal/hepatic impairment: adjust use in patients with compromised kidney or liver function. - Concomitant pyrazolones: do not combine with other drugs of the same class. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Metamizole sodium can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Myelosuppressive agents: increased risk of severe blood dyscrasias. - Anticoagulants: heightened bleeding tendency. - Other NSAIDs: elevated gastrointestinal bleeding risk. - Drugs causing agranulocytosis: additive risk of white‑blood‑cell suppression.

Moderate Interactions (Monitor Closely): - Diuretics: possible alteration of renal electrolyte balance. - Antihypertensives: may enhance potassium loss and affect blood pressure control. - Alcohol: can increase gastrointestinal irritation and central nervous system effects.